(KRON) — The future of one biotech company on the Peninsula is drastically changing. Unity Biotechnology is laying off its entire workforce, the company announced Monday in a press release.

1.1a Congress must establish a National Biotechnology Coordination Office (NBCO) within the Executive Office of the President with a director, appointed by the President, who would coordinate ...

Earlier this week, the congressionally-mandated National Security Commission on Emerging Biotechnology released its major report, titled “Charting the Future of Biotechnology.” The bipartisan ...

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. Congress should ...

A U.S. congressional commission has made the case for “swift action” to maintain the nation’s role as a biotech superpower, while warning the sector is “dangerously close to falling behind ...

The comprehensive report from the bipartisan National Security Commission on Emerging Biotechnology (NSCEB) delivers a “sobering, even frightening,” conclusion: that China is quickly ascending to ...

Biotechnology offers a scalable alternative, but realizing its full potential requires commitment from governments and space agencies. By harnessing biological processes such as microbial and ...

China has captured production of portions of the global biotechnology supply chain to accomplish President Xi Jinping’s goal to “develop effective deterrent against attempts by other countries ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

WITH DIFFERENT BACKGROUNDS FROM ALL OVER THE WORLD... TO NETWORK AND TALK ABOUT THE EVOLUTION OF BIOTECHNOLOGY. "WE ARE ALL CHILDREN FROM FARMWORKERS FROM THE SALINAS VALLEY. PART OF THE GLOBAL ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Biotechnology venture capital is recovering from its slide and investors are expressing optimism about 2025, even as they confront uncertainties weighing on their industry. U.S. and European ...